Navigation Links
Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
Date:10/16/2007

- Presentations on long-term safety and cardiovascular safety of nebulized formoterol fumarate and safety/ efficacy of concomitant use with tiotropium

for treatment of COPD -

NAPA, Calif., Oct. 16 /PRNewswire/ -- Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), announces three clinical data presentations will be given at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP) on Wednesday, October 24, 2007 at the McCormick Place Convention Center in Chicago. Data will be presented from two safety studies that were included as part of the New Drug Application (NDA) filing to the U.S. Food and Drug Administration (FDA) for Perforomist(TM) Inhalation Solution. The third presents results from a Phase IIIb study of the concomitant use of Perforomist(TM) Inhalation Solution with tiotropium for the treatment of COPD.

Perforomist(TM) Inhalation Solution is the first and only FDA-approved nebulized form of formoterol fumarate and is indicated for long-term, twice- daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD). Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

For those attending CHEST, the three presentations are available as follows:

-- "Long-Term Safety of Nebulized Formoterol in COPD: An Open-Label

Active-Control Extension Study" Poster # 239

-- "Cardiovascular Safety of Nebulized Formoterol in COPD Patients: A

Double-Blind, Placebo-Controlled Study" Poster # 238

-- "Safety and Efficacy of Concomitant Treatment with Nebulized Formoterol

and T
'/>"/>

SOURCE Dey, L.P.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
3. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
4. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
5. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
6. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
7. Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
8. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
9. Data supporting three Antisoma programmes presented at AACR
10. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
11. Genetic Analysis Systems Enter the Clinical Mainstream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Argos Therapeutics, Inc. today announced that its late scientific co-founder ... Nobel Prize in medicine for the discovery of dendritic cells ... Steinman,s discovery of dendritic cells and his research of dendritic ... immunity have led to the development of Argos, core technology, ...
... Ingenious Med welcomes Chief Financial Officer, Mark Adams as ... responsible for the company,s financial, accounting, treasury and ongoing ... executive with high growth companies such as Ingenious Med," ... financial background and experience will bring tremendous value to ...
Cached Medicine Technology:Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System 2New Chief Financial Officer, Mark Adams, Joins Ingenious Med 2
(Date:7/31/2015)... ... July 31, 2015 , ... ... Group, Inc. has re-branded their social media profiles to better connect with the ... consumers to communicate, find information, share insights and opinions. The Rally Insurance Group, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a ... Those looking to catch a new and refreshing show on Broadway, look no further ... achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille Lortel ...
(Date:7/31/2015)... ... 31, 2015 , ... Well-known for its unique pastries and delicious confections, Pastry ... custom designs, making life just a little bit sweeter for newlyweds. A family-owned business, ... who orders one. , The bakery provides a full line of custom wedding cakes. ...
(Date:7/31/2015)... ... 2015 , ... As part of their company mission, Dallas pet sitting ... organizations is essential to the longevity of their business. It is for that ... Professional Pet Sitters (NAPPS) annual Presents 4 Pets supply drive. Presents 4 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Creating one of the most modern fertility ... a visionary image that goes beyond the boundaries of fertility medicine. , As ... extraordinary heights with dependable patient support, affordable treatments, unending hope, and high fertility success ...
Breaking Medicine News(10 mins):Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3
... -- About one million packets of birth control pills are ... of a packaging error that could reduce the effectiveness of ... 14 lots of Lo/Ovral-28 tablets and 14 lots of generic ... Pfizer discovered that some blister packs may contain either too ...
... , WEDNESDAY, Feb. 1 (HealthDay News) -- Scientists may one ... lost the ability to speak, new research suggests. In their ... journal PLoS Biology , University of California, Berkeley researchers describe ... waves in order to reconstruct words the person hears in normal ...
... Heart Month, on Wednesday, Feb. 8, 2012, the National Heart, ... the support of the Foundation for the National Institutes of ... Collection 2012 at Mercedes-Benz Fashion Week in New York City. ... Heart Truth has partnered with Million Hearts, a national initiative ...
... Most studies that have examined growing levels of health ... between the "haves" and the "have-nots" in terms of socioeconomic ... study has found, for the first time, that health disparities ... often times more than the disparities have grown between ...
... Reinberg HealthDay Reporter , TUESDAY, Jan. 31 ... 180 prostate genes among men with early stage prostate ... genes known to suppress tumor growth and repair DNA, ... progression of the disease, the researchers said. "There ...
... and 2009, the musculoskeletal (MSK) ultrasound volume increase among ... to a study in the February issue of the ... Ultrasound images of the MSK system provide pictures of ... body. Over the past two decades, MSK ...
Cached Medicine News:Health News:Pfizer Recalls 1 Million Packets of Birth Control Pills 2Health News:Scientists Use Brain Waves to Eavesdrop on the Mind 2Health News:The NIH urges women to protect their heart health 2Health News:The NIH urges women to protect their heart health 3Health News:The NIH urges women to protect their heart health 4Health News:Study reveals new wrinkle in growing US health gap 2Health News:Study reveals new wrinkle in growing US health gap 3Health News:Science Shows How Exercise Might Help in Prostate Cancer 2Health News:Science Shows How Exercise Might Help in Prostate Cancer 3
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
SOC Kit for Bacterial Cells containing 10 x 5mls Sterile growth medium with instructions...
Medicine Products: